Pharvaris NV (Nasdaq: PHVS), a late-stage biopharmaceutical company, has announced the presentation of data at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, highlighting the potential of deucrictibant in preventing and treating bradykinin-mediated angioedema attacks. The data demonstrated deucrictibant's potential to address unmet needs for individuals with bradykinin-mediated diseases, such as hereditary angioedema $(HAE)$ and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). The findings from the CHAPTER-1 and RAPIDe-2 studies indicated sustained attack reduction and improvement in quality of life. Additionally, the upcoming RAPIDe-3 phase 3 on-demand study will explore "end-of-progression" as a new pre-specified endpoint. Currently, there are no approved therapies for AAE-C1INH attacks, and Pharvaris' research aims to fill this gap. The posters with detailed findings are available on the Pharvaris website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.